These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33026771)

  • 1. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
    Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
    J Drugs Dermatol; 2020 Oct; 19(10):985-991. PubMed ID: 33026771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines.
    Kerscher M; Fabi S; Fischer T; Gold M; Joseph J; Prager W; Rzany B; Yoelin S; Roll S; Klein G; Maas C
    J Drugs Dermatol; 2021 Oct; 20(10):1052-1060. PubMed ID: 34636520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aesthetic ONE21 Technique for Injecting IncobotulinumtoxinA into the Forehead: Initial Experience With 86 Patients.
    de Sanctis Pecora C; Bussamara Pinheiro MV; Figueiredo V; Guerra R
    J Drugs Dermatol; 2021 Jan; 20(1):31-37. PubMed ID: 33400422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
    Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
    J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
    Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
    Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
    Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
    J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study.
    Prager W; Bee EK; Havermann I; Zschocke I
    Clin Interv Aging; 2013; 8():449-56. PubMed ID: 23650444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.
    Carruthers A; Carruthers J; Said S
    Dermatol Surg; 2005 Apr; 31(4):414-22; discussion 422. PubMed ID: 15871316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
    Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
    Beer KR; Shamban AT; Avelar RL; Gross JE; Jonker A
    Dermatol Surg; 2019 Nov; 45(11):1381-1393. PubMed ID: 30893162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of IncobotulinumtoxinA for the treatment of platysmal bands of the aging neck: an open-label, prospective pilot study.
    Gubanova EI; Panova OS; Sanchez EA; Rodina MY; Starovatova PA
    J Drugs Dermatol; 2013 Dec; 12(12):1461-6. PubMed ID: 24301249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE; Song EJ; Choi GS; Lew BL; Sim WY; Kang H
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
    Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
    J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a Randomized, Double-Blind, Placebo-Controlled, Phase III Study.
    Kerscher M; Rzany B; Prager W; Turnbull C; Trevidic P; Inglefield C
    Dermatol Surg; 2015 Oct; 41(10):1149-57. PubMed ID: 26359996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
    Grimes PE; Shabazz D
    Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Patient-Reported Outcomes, and Safety in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines.
    Keaney TC; Cavallini M; Leys C; Rossi A; Drinkwater A; Manson Brown S; Garcia JK; Mao C
    Dermatol Surg; 2020 Feb; 46(2):229-239. PubMed ID: 31343446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.